“Spesolimab Increases the Percentage of Generalized Pustular Psoriasis (GPP) Patients With Clear Skin over Time As Measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s490, https://doi.org/10.25251/skin.8.supp.490.